crystal
structur
capsom
protein
data
bank
pdb
code
use
templat
amino
acid
sequenc
repres
psv
model
three
amino
acid
residu
differ
sequenc
crystal
psv
two
positon
ef
loop
one
posit
fg
loop
sequenc
differ
appear
advers
impact
upon
qualiti
homolog
model
global
model
qualiti
estim
gmqe
score
homolog
model
repres
remain
genotyp
produc
gmqe
score
crystal
structur
capsom
pdb
code
use
control
evalu
structur
accuraci
psv
homolog
model
base
upon
crystal
structur
pairwis
comparison
homolog
model
crystal
structur
superimposit
demonstr
root
mean
squar
rm
deviat
pairwis
model
comparison
carri
psv
homolog
model
homolog
model
individu
nonvaccin
psv
loop
fig
analys
predict
chang
two
model
fig
distanc
alter
loop
structur
summaris
fig
superimposit
nonvaccin
homolog
model
onto
homolog
model
gener
follow
rm
deviat
estim
loop
distanc
homolog
model
consid
signific
distanc
measur
nonvaccin
genotyp
individu
loop
greater
rm
valu
gener
pairwis
comparison
homolog
model
structur
chang
bc
loop
predict
nonvaccin
genotyp
except
fig
shift
bc
loop
compar
rang
mean
sd
fig
predict
structur
chang
appear
attribut
insert
addit
amino
acid
residu
bc
loop
comparison
structur
chang
de
loop
predict
homolog
model
repres
nonvaccin
genotyp
compar
fig
de
encircl
lumen
capsom
fig
loop
contain
insert
delet
within
amino
acid
sequenc
nonvaccin
genotyp
rel
nonvaccin
homolog
model
predict
structur
chang
ef
loop
compar
model
fig
genotyp
singl
amino
acid
residu
delet
within
ef
loop
correspond
within
ef
loop
may
contribut
toward
mean
ef
loop
shift
compar
fig
contrast
predict
structur
chang
ef
loop
underpin
amino
acid
residu
insert
delet
comparison
structur
chang
fg
loop
predict
fig
mean
fg
loop
shift
compar
respect
fig
genotyp
fg
loop
amino
acid
residu
delet
correspond
insert
comparison
appear
influenc
predict
structur
chang
fg
amino
acid
sequenc
contain
residu
delet
insert
comparison
structur
chang
fg
loop
predict
nonvaccin
genotyp
compar
hi
loop
amino
acid
residu
delet
correspond
within
hi
loop
three
homolog
model
repres
nonvaccin
genotyp
predict
structur
chang
compar
homolog
model
within
hi
loop
comparison
structur
chang
predict
fig
predict
structur
differ
loop
nonvaccin
psv
compar
psv
use
inform
design
chimer
psv
intergenotyp
loop
swap
reason
loop
nonvaccin
genotyp
present
similar
topographi
correspond
loop
like
recognis
vaccineinduc
crossneutralis
antibodi
base
upon
rational
de
loop
consid
candid
investig
base
upon
predict
structur
similar
de
loop
nonvaccin
genotyp
compar
fig
contrast
frequenc
predict
structur
diverg
observ
bc
ef
loop
fig
nonvaccin
genotyp
negat
investig
two
loop
fg
hi
loop
fig
f
chosen
investig
base
upon
predict
structur
similar
nonvaccin
genotyp
frequent
recognis
crossneutralis
panel
chimer
psv
intergenotyp
de
fg
hi
loop
swap
isol
combin
design
gener
loop
swap
made
genotyp
recognis
crossneutralis
antibodi
chosen
background
control
sinc
crossneutralis
antibodi
demonstr
minim
recognit
genotyp
number
amino
acid
residu
substitut
differ
three
loop
de
longest
loop
five
posit
residu
vari
thirti
residu
long
fg
loop
eleven
variabl
posit
whilst
hi
shortest
loop
vari
nine
sixteen
amino
acid
posit
psv
either
backbon
singl
de
fg
hi
doubl
defg
dehi
fghi
tripl
defghi
loop
swap
fig
gener
similarlys
particl
particletoinfect
pi
ratio
exampl
psv
backbon
produc
median
pi
ratio
iqr
compar
pi
ratio
iqr
produc
psv
backbon
fig
thirtysix
hpv
vaccine
sera
n
n
test
chimer
psv
crossneutralis
titr
gener
chimer
psv
backbon
compar
psv
whilst
titr
gener
chimer
psv
backbon
compar
psv
fig
reason
introduct
loop
backbon
would
result
reduct
crossneutralis
antibodi
recognit
incorpor
hi
loop
alon
result
reduct
crossneutralis
antibodi
recognit
howev
incorpor
de
loop
fig
reduc
crossneutralis
antibodi
recognit
median
iqr
wilcoxon
pair
signedrank
test
p
largest
impact
singl
combin
loop
swap
observ
fg
loop
alon
result
median
decreas
crossneutralis
antibodi
recognit
iqr
p
compar
psv
transfer
crossneutralis
antibodi
recognit
support
either
introduct
de
hi
loop
backbon
signific
effect
crossneutralis
antibodi
recognit
produc
geometr
mean
titr
gmt
ci
p
ci
p
respect
compar
psv
titr
ci
fig
convers
introduct
fg
loop
backbon
significantli
increas
crossneutralis
antibodi
recognit
psv
effect
dramat
fg
loop
combin
de
loop
result
median
increas
crossneutralis
antibodi
recognit
iqr
p
compar
psv
crossneutralis
antibodi
recognit
chimer
psv
independ
hpv
vaccin
receiv
exampl
replac
fg
loop
within
backbon
result
median
iqr
p
iqr
p
decreas
rel
psv
sera
respect
replac
de
fg
loop
within
backbon
significantli
increas
recognit
psv
gmt
ci
gmt
ci
gmt
ci
p
sera
gmt
ci
p
order
predict
residu
within
de
fg
loop
may
involv
epitop
footprint
recognis
vaccineinduc
crossneutralis
antibodi
de
fg
loop
amino
acid
sequenc
align
fig
amino
acid
posit
vaccin
type
crossneutralis
antibodi
target
share
residu
background
control
identifi
de
fg
loop
residu
select
undergo
sitedirect
mutagenesi
determin
contribut
epitop
footprint
recognis
crossneutralis
antibodi
alongsid
addit
site
residu
differ
de
fg
fig
panel
seven
chimer
psv
backbon
de
fg
loop
swap
gener
chimer
psv
harbour
singl
doubl
amino
acid
residu
switch
incorpor
either
de
fg
loop
wherebi
amino
acid
present
swap
amino
acid
present
posit
fig
psv
particl
gener
similar
size
similar
pi
ratio
subset
twentyfour
hpv
vaccine
sera
n
n
origin
panel
thirtysix
test
seven
new
chimer
psv
crossneutralis
titr
gener
compar
chimer
psv
backbon
de
fg
loop
fig
within
de
loop
amino
acid
switch
result
signific
reduct
crossneutralis
antibodi
recognit
howev
dual
amino
switch
reduc
crossneutralis
antibodi
recognit
median
iqr
wilcoxon
pair
signedrank
test
p
amino
acid
switch
within
fg
separ
earli
region
number
late
region
loop
dual
amino
acid
switch
within
late
region
result
signific
reduct
crossneutralis
antibodi
recognit
howev
dramat
impact
observ
dual
amino
acid
delet
posit
produc
crossneutralis
titr
gmt
ci
p
lower
titr
observ
psv
ci
fig
contrast
dual
amino
acid
switch
posit
within
earli
region
result
reduct
crossneutralis
antibodi
recognit
map
mutagenis
residu
within
de
fg
loop
homolog
model
demonstr
posit
surfaceexpos
capsid
fig
amino
acid
posit
within
late
region
fg
biggest
impact
upon
crossneutralis
antibodi
recognit
cluster
togeth
intersect
fg
de
loop
studi
attempt
delin
domain
recognis
hpv
vaccineinduc
crossneutralis
antibodi
design
gener
chimer
psv
intergenotyp
loop
swap
test
sensit
crossneutralis
antibodi
elicit
hpv
vaccin
crossneutralis
antibodi
detect
follow
immunis
vlp
recognis
psv
repres
number
nonvaccin
reason
assum
protein
nonvaccin
genotyp
harbour
antigen
domain
present
similar
topographi
order
identifi
domain
crystallograph
homolog
model
repres
amino
acid
sequenc
psv
gener
utilis
comparison
loop
structur
predict
structur
differ
nonvaccin
genotyp
common
bc
ef
loop
locat
outer
rim
capsom
occur
less
frequent
fg
hi
loop
structur
differ
predict
centrallyposit
de
loop
surfaceexpos
loop
region
hpv
capsid
demonstr
higher
degre
sequenc
heterogen
core
region
evid
higher
level
intra
intergenotyp
amino
acid
variabl
locat
thought
divers
driven
pressur
escap
neutralis
antibodi
target
epitop
within
surfac
expos
amino
acid
residu
within
loop
also
appear
play
critic
role
maintain
capsid
initi
virushost
may
account
structur
similar
predict
nonvaccin
genotyp
loop
comput
model
protein
interact
suggest
region
de
fg
loop
interact
prolinerich
region
whilst
cystein
residu
within
ef
loop
crucial
format
intercapsomer
disulphid
addit
bc
fg
hi
loop
contain
lysin
residu
facilit
bind
heparin
sulfat
proteoglycan
initi
step
requir
success
hpv
analysi
loop
structur
within
studi
interpret
caveat
structur
predict
deriv
homolog
model
repres
psv
amino
acid
sequenc
rather
resolv
crystal
structur
nevertheless
homolog
model
standard
approach
use
pandem
order
predict
locat
antigen
domain
site
proteinprotein
interact
pairwis
comparison
homolog
model
base
upon
capsom
crystal
structur
capsom
crystal
demonstr
close
structur
relationship
data
impli
absenc
avail
crystal
structur
homolog
model
util
surrog
structur
predict
structur
differ
protein
loop
investig
extens
use
vlp
target
antigen
antibodi
recognit
manipul
individu
loop
insert
foreign
bcell
epitop
hiv
hbv
identifi
fg
hi
loop
immunogen
region
loop
amino
acid
point
mutat
vlp
complet
intergenotyp
loop
switch
identifi
residu
contribut
epitop
footprint
recognis
typespecif
neutralis
murin
use
function
chimer
psv
measur
antibodi
specif
capabl
neutralis
psv
infect
howev
limit
singl
construct
bc
loop
swap
use
map
epitop
mab
limit
use
chimer
psv
antigen
target
may
reflect
reduc
toler
complex
particl
manipul
within
present
studi
chimer
psv
consist
intergenotyp
loop
swap
two
genotyp
within
speci
group
approach
result
success
format
function
chimer
psv
particl
chimer
psv
utilis
antigen
viru
system
includ
avian
jc
map
polyclon
antibodi
recognit
specif
antigen
domain
chimer
psv
demonstr
fg
loop
necessari
suffici
epitop
footprint
signific
proport
crossneutralis
antibodi
specif
de
loop
appear
enhanc
recognit
hi
loop
appear
contribut
toward
crossneutralis
antibodi
recognit
two
loop
appear
contribut
toward
major
identifi
mab
epitop
although
instanc
singl
loop
support
epitop
footprint
exampl
bc
loop
alon
target
epitop
footprint
four
neutralis
mab
recent
resolv
use
cryoelectron
microscop
analysi
demonstr
first
time
alongsid
fg
hi
loop
residu
residu
de
loop
form
core
epitop
minor
contribut
residu
bc
ef
amino
acid
residu
within
de
loop
also
form
major
epitop
footprint
recognis
neutralis
human
mab
isol
hpv
vaccin
present
studi
found
de
loop
enhanc
crossneutralis
antibodi
recognit
fg
loop
within
backbon
enhanc
may
result
de
loop
residu
function
part
epitop
footprint
mayb
due
de
loop
interact
support
optimum
present
fg
loop
finemap
epitop
footprint
recognis
crossneutralis
antibodi
undertaken
wherebi
residu
de
fg
loop
amino
acid
posit
differ
subject
sitedirect
mutagenesi
alongsid
site
residu
variabl
three
genotyp
crossneutralis
antibodi
appear
primarili
target
amino
acid
residu
locat
late
region
fg
loop
particularli
amino
acid
posit
delet
result
almost
complet
loss
recognit
crossneutralis
antibodi
contrast
mutat
two
amino
acid
posit
earli
region
fg
loop
effect
upon
crossneutralis
antibodi
recognit
indic
earli
region
target
antibodi
specif
fg
loop
contain
number
mediat
primari
host
interact
inhibit
vivo
vaccin
induc
provid
possibl
mechanist
reason
behind
antigen
target
fg
loop
typespecif
mab
natur
infect
earli
region
fg
loop
known
harbour
residu
involv
epitop
footprint
typespecif
neutralis
whilst
late
region
contain
major
residu
involv
epitop
footprint
typespecif
neutralis
data
studi
appear
demonstr
late
region
fg
loop
harbour
amino
acid
residu
recognis
hpv
vaccineinduc
crossneutralis
antibodi
direct
overlap
exist
residu
typespecif
antibodi
footprint
observ
suggest
typespecif
antibodi
crossneutralis
antibodi
gener
recognis
differ
domain
domain
recognis
crossneutralis
antibodi
subdomin
within
epitop
footprint
typespecif
antibodi
crossneutralis
antibodi
appear
recognis
singl
nonvaccin
genotyp
multipl
nonvaccin
genotyp
addit
like
antibodi
specif
target
distinct
overlap
epitop
footprint
share
common
domain
gener
mab
crossneutralis
nonvaccin
genotyp
may
understand
domain
recognis
crossneutralis
vaccin
antibodi
relationship
typespecif
epitop
context
capsid
surfac
propos
domain
recognis
intergenotyp
crossneutralis
antibodi
elicit
hpv
vaccin
compris
residu
within
late
region
fg
loop
possibl
stabilis
one
residu
within
de
loop
crossneutralis
antibodi
target
domain
may
play
role
hpv
vaccineinduc
crossprotect
homolog
model
creat
amino
acid
sequenc
psv
repres
sequenc
avail
http
homeccrcancergovlcopackaginghtm
use
swiss
model
http
swissmodelexpasyorg
crystal
structur
capsom
pdb
code
use
templat
target
amino
acid
sequenc
psv
model
qualiti
predict
model
measur
gmqe
score
rang
repres
expect
accuraci
result
model
score
indic
highest
level
qualiti
estim
deepview
swisspdb
viewer
use
perform
pairwis
model
comparison
superimposit
predict
structur
differ
model
measur
superimposit
homolog
model
support
rm
valu
repres
averag
distanc
correspond
atom
two
model
lower
rm
valu
closer
two
model
relat
model
compar
gener
rm
valu
crystal
structur
capsom
pdb
code
use
pairwis
comparison
control
homolog
model
deepview
programm
addit
use
model
posit
amino
acid
residu
interest
homolog
model
gene
backbon
reciproc
intergenotyp
loop
swap
synthesis
thermo
fisher
scientif
applic
sitedirect
mutagenesi
carri
use
quikchang
kit
stratagen
gene
subclon
plasmid
conjunct
rapid
dna
depho
ligat
kit
roch
chimer
psv
carri
luciferas
report
express
purifi
previous
particl
format
size
determin
electron
microscop
analysi
neg
stain
particl
ten
psv
particl
measur
nanometr
nm
prepar
median
diamet
interquartil
rang
calcul
fig
equival
tissu
cultur
infecti
dose
estim
psv
prepar
use
spearmankarb
equat
standardis
input
use
concentr
psv
stock
estim
semiquantit
western
blot
analysi
use
antibodi
abcam
unit
kingdom
particletoinfect
ratio
determin
basi
estim
particl
amount
particl
per
ng
protein
http
homeccrcancergovlcoproductionasp
ratio
normal
input
volum
serum
sampl
avail
year
old
girl
randomis
receiv
three
dose
part
phase
iv
clinic
trial
compar
hpv
vaccin
immunogen
wwwclinicaltrialsgov
rec
number
subset
sampl
n
n
taken
month
receiv
final
dose
select
analysi
base
upon
crossneutralis
antibodi
sampl
subject
serial
dilut
antibodi
titr
result
reduct
luciferas
signal
produc
control
well
contain
psv
cell
estim
interpol
hpv
antibodi
control
reagent
includ
assay
alongsid
heparin
sigmaaldrich
use
posit
inhibitor
control
median
heparin
concentr
psv
iqr
n
iqr
n
median
neutralis
titr
posit
antibodi
control
reagent
high
titr
psv
iqr
n
iqr
n
neg
antibodi
control
reagent
hpv
neg
titr
assay
n
wilcoxon
pair
signedrank
test
use
comparison
crossneutralis
antibodi
titr
differ
psv
target
test
perform
use
statist
packag
stata
statacorp
lp
cite
articl
bissett
l
et
al
de
fg
loop
hpv
major
capsid
protein
contribut
epitop
vaccineinduc
crossneutralis
antibodi
sci
rep
doi
publish
note
springer
natur
remain
neutral
regard
jurisdict
claim
publish
map
institut
affili
